Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts
AIM: To assess heterogeneity in adherence to medications in two example comparative effectiveness research studies.
PATIENTS & METHODS: We analyzed data from commercially insured patients initiating a statin or anticoagulant during 2005-2012. We calculated the cross-validated R2 from a series of hierarchical linear models to assess variation in 1-year adherence.
RESULTS: There was less heterogeneity in adherence in the statin cohort compared with the anticoagulant cohort, where patient characteristics explained 7.2% of variation in adherence, and adding therapy and provider characteristics increased the proportion of variation explained to 8.0 and 8.5%, cumulatively. Random effects provided essentially no explanatory power, even in the statin cohort with large numbers of patients clustered within each pharmacy, prescriber and provider.
CONCLUSION: The dependence of adherence on the healthcare system was stronger when the healthcare system influenced treatment choice and patient access to medication and when indications for treatment were strong.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 6(2017), 7 vom: 03. Okt., Seite 613-625 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Franklin, Jessica M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adherence |
|---|
| Anmerkungen: |
Date Completed 07.06.2019 Date Revised 07.06.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/cer-2016-0095 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM277083559 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM277083559 | ||
| 003 | DE-627 | ||
| 005 | 20231225013421.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/cer-2016-0095 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0923.xml |
| 035 | |a (DE-627)NLM277083559 | ||
| 035 | |a (NLM)29039693 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Franklin, Jessica M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Variation in adherence to medications across the healthcare system in two comparative effectiveness research cohorts |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 07.06.2019 | ||
| 500 | |a Date Revised 07.06.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a AIM: To assess heterogeneity in adherence to medications in two example comparative effectiveness research studies | ||
| 520 | |a PATIENTS & METHODS: We analyzed data from commercially insured patients initiating a statin or anticoagulant during 2005-2012. We calculated the cross-validated R2 from a series of hierarchical linear models to assess variation in 1-year adherence | ||
| 520 | |a RESULTS: There was less heterogeneity in adherence in the statin cohort compared with the anticoagulant cohort, where patient characteristics explained 7.2% of variation in adherence, and adding therapy and provider characteristics increased the proportion of variation explained to 8.0 and 8.5%, cumulatively. Random effects provided essentially no explanatory power, even in the statin cohort with large numbers of patients clustered within each pharmacy, prescriber and provider | ||
| 520 | |a CONCLUSION: The dependence of adherence on the healthcare system was stronger when the healthcare system influenced treatment choice and patient access to medication and when indications for treatment were strong | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a adherence | |
| 650 | 4 | |a comparative effectiveness research | |
| 650 | 4 | |a mixed models | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 650 | 7 | |a Hydroxymethylglutaryl-CoA Reductase Inhibitors |2 NLM | |
| 700 | 1 | |a Donneyong, Macarius M |e verfasserin |4 aut | |
| 700 | 1 | |a Desai, Rishi J |e verfasserin |4 aut | |
| 700 | 1 | |a Markson, Leona |e verfasserin |4 aut | |
| 700 | 1 | |a Girman, Cynthia J |e verfasserin |4 aut | |
| 700 | 1 | |a McKay, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Patel, Mehul D |e verfasserin |4 aut | |
| 700 | 1 | |a Mavros, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Schneeweiss, Sebastian |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 6(2017), 7 vom: 03. Okt., Seite 613-625 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2017 |g number:7 |g day:03 |g month:10 |g pages:613-625 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/cer-2016-0095 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2017 |e 7 |b 03 |c 10 |h 613-625 | ||